Grant name: Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
Funding organization: National Cancer Institute (NCI), Department of Health and Human Services
Total funding amount: Up to $500,000 per year for UG3 phase; up to $750,000 per year for UH3 phase
Duration: Maximum of 2 years for UG3 phase; maximum of 4 years for UH3 phase
Primary objective: Accelerate development of evidence-based cancer-related interventions
Key stakeholders: Individuals, caregivers, practitioners, organizations, healthcare systems, public health settings, communities, policymakers
Funding source: National Institutes of Health
Funding type: Cooperative agreement
Significance: Addresses gaps in cancer-related interventions for diverse populations
Grant frequency: Recurring
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits (with and without 501(c)(3) status)
For-Profit Organizations (including Small Businesses)
Local, State, County, and City Governments
Indian/Native American Tribal Governments (both Federally Recognized and not)
Federal Government Agencies
Public Housing Authorities
Faith-based or Community-based Organizations
Regional Organizations
Organizations must be based in the U.S.
Foreign organizations are not eligible to apply, but foreign components of U.S. organizations are allowed
Cancer-related interventions across the cancer control continuum
Focus on populations experiencing health disparities
Interventions may include behavioral, technology-mediated, community-based, healthcare delivery, and multilevel interventions
Improvement in cancer-related outcomes such as clinical health outcomes, health status, health behaviors, quality of care, and healthcare utilization
Research team must have multidisciplinary expertise necessary for conducting pragmatic trials
UG3 phase: Maximum of $500,000 in direct costs per year
UH3 phase: Maximum of $750,000 in direct costs per year
Open Date: January 14, 2025
Application Due Dates: Various deadlines until October 17, 2025
Earliest Start Date: February 14, 2025
Must comply with NIH and Office for Human Research Protections (OHRP) policies regarding human subjects
Applications must follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide